Condition: Prodromal Schizophrenia · Sponsor: China Medical University Hospital
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia deserves study.
This description comes directly from the study's public registry record.
Hsien-Yuan Lane, M.D., Ph.D · 886 4 22052121 · hylane@gmail.com
Always discuss trial participation with your own doctor first.
| Department of Psychiatry, China Medical University Hospital | Taichung, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05052853